¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2022³â Á¦5Â÷ ³»°úºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À° : 2022-06-04

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2022³â Á¦5Â÷ ³»°úºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À° : 2022-06-04
±³À°ÀÏÀÚ : 2022-06-04
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2022³â Á¦5Â÷ ³»°úºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À°
ÁÖÃÖ±â°ü : ´ëÇѳ»°úÇÐȸ
´ã´çÀÚ : ´ëÇѳ»°úÇÐȸ
¿¬¶ôó : 02-793-4364  
À̸ÞÀÏ : kaim4364@kaim.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 1500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 31 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í »çÀüµî·Ï: (³»°úÀü°øÀÇ¡¤Àü¹®ÀÇ) 50,000¿ø / (Ÿ°ú/ºñȸ¿ø) 70,000¿ø / ´çÀϵî·Ï: (³»°úÀü°øÀÇ¡¤Àü¹®ÀÇ) 60,000¿ø / (Ÿ°ú/ºñȸ¿ø) 80,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ08:30~09:00 Frontline Treatment for Multiple Myeloma  ±èÁø¼®(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ09:00~09:30 Optimal Treatment Strategy for PTCL  ¾ç´öȯ(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ09:30~10:00 Frontline Treatment for MDS  ¹®¿µÃ¶(ÀÌÈ­ÀÇ´ë) 
±âŸ 06-04 ¿Â¶óÀΠ10:00~10:05 ºÐ°úÀüÀÓÀÇ ¼ö·Ã±â·Ï µî °øÁö  À̹οµ(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ10:30~11:00 Head & Neck Cancer  À̼¼ÈÆ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ11:00~11:30 Biliary & Pancreas Cancer  ±èÁø¿ø(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ11:30~12:00 Management of Immunotherapy Related Toxicities  °í¼¼ÀÏ(°æ»óÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ12:00~12:30 Immunizations in Adults with Cancer  ÀÌÀºÁ¤(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ08:30~08:55 Acute coronary syndrome¿¡¼­ »õ·Î¿î P2Y12 ¾ïÁ¦Á¦ÀÇ ¿ªÇÒ  È«¿µÁØ(Àü³²ÀÇ´ë) 
Åä·Ð 06-04 ¿Â¶óÀΠ08:55~09:00 Q&A  È«¿µÁØ(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ09:00~09:25 ÀÌ»óÁöÁúÇ÷Áõ ȯÀÚ¿¡¼­ PCSK9¾ïÁ¦Á¦ÀÇ ¿ªÇÒ  ±èº´Áø(¼º±Õ°üÀÇ´ë) 
Åä·Ð 06-04 ¿Â¶óÀΠ09:25~09:30 Q&A  ±èº´Áø(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ09:30~09:55 ½É¹æ¼¼µ¿ ºñ¾à¹° ¸®µëÁ¶Àý¹ý ÃֽŠÁö°ß (Cryoablation µî)  ±èÁø¼®(°í·ÁÀÇ´ë) 
Åä·Ð 06-04 ¿Â¶óÀΠ09:55~10:00 Q&A  ±èÁø¼®(°í·ÁÀÇ´ë) 
±âŸ 06-04 ¿Â¶óÀΠ10:00~10:05 ºÐ°úÀüÀÓÀÇ ¼ö·Ã±â·Ï µî °øÁö  ³ªÁø¿À(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ10:30~10:55 Updated International and Korean Hypertension Guidelines – Review of Current Recommendations  ÃÖ¼ºÈÆ(ÇѸ²ÀÇ´ë) 
Åä·Ð 06-04 ¿Â¶óÀΠ10:55~11:00 Q&A  ÃÖ¼ºÈÆ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ11:00~11:25 Recent Update of Aortic Stenosis Trial and Management  ÃÖö¿õ(°í·ÁÀÇ´ë) 
Åä·Ð 06-04 ¿Â¶óÀΠ11:25~11:30 Q&A  ÃÖö¿õ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ11:30~11:55 Recent Update on Heart Failure Guidelines - What  ±èÀÎö(°è¸íÀÇ´ë) 
Åä·Ð 06-04 ¿Â¶óÀΠ11:55~12:00 Q&A  ±èÀÎö(°è¸íÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ12:00~12:25 Updates in Cardiac Implantable Electronic Devices  ¿ÀÀÏ¿µ(¼­¿ïÀÇ´ë) 
Åä·Ð 06-04 ¿Â¶óÀΠ12:25~12:30 Q&A  ¿ÀÀÏ¿µ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ08:30~09:15 Asthma-COPD Overlap in Korea  ¹Ý°¡¿µ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ09:15~10:00 How to Step Down in Patients with Well-Controlled Asthma?  ±è¼öÁ¤(°æºÏÀÇ´ë) 
±âŸ 06-04 ¿Â¶óÀΠ10:00~10:05 ºÐ°úÀüÀÓÀÇ ¼ö·Ã±â·Ï µî °øÁö  ÀÌ»ó¹Î(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ10:30~11:10 Practical Diagnostic Approach to Drug Allergy  ÃÖ±æ¼ø(°í½ÅÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ11:10~11:50 HLA Allele and Drug Hypersensitivity  ¹Ú¼Ò¿µ(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ11:50~12:30 Hypersensitivity Reaction to COVID-19 Vaccine  ÀÌ¿ë¿ø(°üµ¿ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ08:30~09:00 Novel Treatments in Systemic Lupus Erythematosus  °û½Â±â(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ09:00~09:30 Interstitial Lung Disease Assoicated with Rheumatic Diseases  ±èÇö¼÷(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ09:30~10:00 Large Vessel Vasculitis : Updated Treatment Guideline  ÃÖÂù¹ü(ÇѾçÀÇ´ë) 
±âŸ 06-04 ¿Â¶óÀΠ10:00~10:05 ºÐ°úÀüÀÓÀÇ ¼ö·Ã±â·Ï µî °øÁö  ±è±ÙÅÂ(°í½ÅÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ10:30~11:00 Scleromyxedema with Multiple Systemic Involvement: A Case Report  ÀÌ°æ¾ð(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ11:00~11:30 Development of Peripheral Spondyloarthritis after COVID-19 in The HLA-B27-Positive Monozygotic Twins: With A Single Cell Tranome Profiling  ±èÁ¤°ï(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ11:30~12:00 A Patient with Late-on Limb-Girdle Muscular Dystrophy Type 2B Mimicking Dermatomyositis: A Case Report and Review  ±è¹ÎÁ¤(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ12:00~12:30 Transient Systemic Lupus Erythematosus-like Syndrome Associated With Parvovirus B19 Infection: A Case Report  ±è¹®¿µ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ08:30~09:00 Update in Approach to Patients with Diabetes Insipidus  ±èÇý¼ø(°è¸íÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ09:00~09:30 Medical Management of Hyperprolactinemia  ÇÏÁ¤ÈÆ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ09:30~10:00 Medical Management of Cushing¡¯s Disease  ±¸Ã¶·æ(¿¬¼¼ÀÇ´ë) 
±âŸ 06-04 ¿Â¶óÀΠ10:00~10:05 ºÐ°úÀüÀÓÀÇ ¼ö·Ã±â·Ï µî °øÁö  ±è¼ö°æ(Â÷ÀÇ°úÇдëÇÐ) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ10:30~11:00 Management of Thyroid Nodules with AUS/FLUS Results  ½Åµ¿¿±(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ11:00~11:30 Management of Low- to Intermediate Risk Thyroid Cancer  ¹Ú¿µÁÖ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ11:30~12:00 Practical Points of RAI Treatment Cancer and Graves Disease  ±è¹ÎÈñ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ12:00~12:30 When and How to Treat Subclinical Thyroid Dysfunction  À¯¿ø»ó(´Ü±¹ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ13:30~13:55 Differential Diagnosis of Ascites  Á¶ÁÖ¿¬(Á¶¼±ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ13:55~14:15 Recent Update on the Management of Chronic Hepatitis C  °­¹Î±Ô(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ14:15~14:40 Diagnosis and Management of Cholangiocarcinoma  Á¶Àº¾Ö(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ14:40~15:00 Diagnosis and Management of Chronic Pancreatitis  ÀÌÅÂÀ±(°Ç±¹ÀÇ´ë) 
±âŸ 06-04 ¿Â¶óÀΠ15:00~15:05 ºÐ°úÀüÀÓÀÇ ¼ö·Ã±â·Ï µî °øÁö  ÀÌÇö¿õ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ15:30~16:00 Recent Advances on Gastric Subepithelial Tumor  ±èµµÈÆ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ16:00~16:30 Diagnosis and Management of Peptic Ulcer Disease  ¼­½ÂÀÎ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ16:30~17:00 Colonoscopy: Quality Indicators  °û¹Î¼·(°æÈñÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ17:00~17:30 Diagnosis and Management of Chronic Diarrhea  ±è¿ë¼º(¿ø±¤ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ13:30~14:15 Preventing Transmission of Multidrug Resistant Gram-Negatives in Hospitalised Patients  ±èŹ(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ14:15~15:00 Innovative Uses of MALDI-TOF and Other Rapid Diagnositc Tests in the Clinical Microbiology Lab  ¹ÚÁ¤¼ö(¼­¿ïÀÇ´ë) 
±âŸ 06-04 ¿Â¶óÀΠ15:00~15:05 ºÐ°úÀüÀÓÀÇ ¼ö·Ã±â·Ï µî °øÁö  ±èÃæÁ¾(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ15:30~16:10 Clostridioides Difficile 2021 Focused Update  À±¿µ°æ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ16:10~16:50 IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections  °­Ã¶ÀÎ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ16:50~17:30 Vancomycin  ¼Û°æÈ£(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ13:30~13:55 Update in the pathogenesis and Tx of IgAN  Á¤°æȯ(°æÈñÀÇ´ë) 
Åä·Ð 06-04 ¿Â¶óÀΠ13:55~14:00 Q&A  Á¤°æȯ(°æÈñÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ14:00~14:25 Update in the treatment of MCD and FSGS  ¹ÝÅÂÇö(°¡Å縯ÀÇ´ë) 
Åä·Ð 06-04 ¿Â¶óÀΠ14:25~14:30 Q&A  ¹ÝÅÂÇö(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ14:30~14:55 Diagnosis and treatment of MPGN  À̹ÌÁ¤(Â÷ÀÇ°úÇдëÇÐ) 
Åä·Ð 06-04 ¿Â¶óÀΠ14:55~15:00 Q&A  À̹ÌÁ¤(Â÷ÀÇ°úÇдëÇÐ) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ15:00~15:25 Anti-podocyte antibody and MGN  ÃÖÈÆ¿µ(¿¬¼¼ÀÇ´ë) 
Åä·Ð 06-04 ¿Â¶óÀΠ15:25~15:30 Q&A  ÃÖÈÆ¿µ(¿¬¼¼ÀÇ´ë) 
±âŸ 06-04 ¿Â¶óÀΠ15:30~15:35 ºÐ°úÀüÀÓÀÇ ¼ö·Ã±â·Ï µî °øÁö  ¹®ÁÖ¿µ(°æÈñÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ16:00~16:25 Atypical HUS  ÀÌÁ¤Ç¥(¼­¿ïÀÇ´ë) 
Åä·Ð 06-04 ¿Â¶óÀΠ16:25~16:30 Q&A  ÀÌÁ¤Ç¥(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ16:30~16:55 Lupus Nephritis  Â÷ÁøÁÖ(°í·ÁÀÇ´ë) 
Åä·Ð 06-04 ¿Â¶óÀΠ16:55~17:00 Q&A  Â÷ÁøÁÖ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ17:00~17:25 ANCA-associated GN  ±è±âÇ¥(ÀÎÇÏÀÇ´ë) 
Åä·Ð 06-04 ¿Â¶óÀΠ17:25~17:30 Q&A  ±è±âÇ¥(ÀÎÇÏÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ13:30~14:00 PreCOPD & COPD: Early Diagnosis & Treatment  È²¿ëÀÏ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ14:00~14:30 Update on the Role of Inhaled Corticosteroids in Chronic Airway Diseases  ³ª½Â¿ø(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ14:30~15:00 Update on the Biologics in Chronic Airway Diseases  ¹®Áö¿ë(ÇѾçÀÇ´ë) 
±âŸ 06-04 ¿Â¶óÀΠ15:00~15:05 ºÐ°úÀüÀÓÀÇ ¼ö·Ã±â·Ï µî °øÁö  ¹Ú¿ë¹ü(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ15:30~16:00 Update on the Treatment of ARDS  ±è¿ø¿µ(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ16:00~16:30 Management of Severe COVID-19 Patients & Post-Discharge Care  ±èÁÖÇý(±¹¸³Áß¾ÓÀÇ·á¿ø) 
±³À°½Ã°£ 06-04 ¿Â¶óÀΠ16:30~17:00 Update on the Critical Care Procedures  Á¶¿ìÇö(ºÎ»êÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2022³â Á¦5Â÷ ³»°úºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À° : 2022-06-04""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022 ¼Ò¾Æû¼Ò³â ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ 1Â÷ ½ÉÆ÷Áö¾ö : 2022-06-04
´ÙÀ½±Û Á¦27Â÷ ´ëÇÑÁÖ»êÀÇÇÐȸ Ãá°è¿¬¼ö°­Á : 2022-06-04
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 18 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 20 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 17 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 11 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 16 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 21 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 4 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 9 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 9 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 7 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 7 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 5 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 8 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 9 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 11 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷